APEIRON Biologics is a privately held European biotech company based in Vienna, Austria, focused on the discovery and development of treatments for respiratory diseases and novel cancer immunotherapies.
Our company has a well balanced portfolio with one product on the market and several promising products from clinical to pre-clinical stages. As for the product on the market, APEIRON received EU marketing approval for APN311 (Dinutuximab beta, Qarziba®) in May 2017 for the treatment of pediatric neuroblastoma patients. We out-licensed Qarziba® globally to EUSA Pharma Ltd, for which it holds exclusive rights to this product.
APEIRON’s key projects and technologies are bolstered by a strong patent portfolio with broad territorial coverage. Our development expertise is validated through partnerships with leading global pharmaceutical companies and academic institutions.
Our company has a well balanced portfolio with one product on the market and several promising products from clinical to pre-clinical stages. As for the product on the market, APEIRON received EU marketing approval for APN311 (Dinutuximab beta, Qarziba®) in May 2017 for the treatment of pediatric neuroblastoma patients. We out-licensed Qarziba® globally to EUSA Pharma Ltd, for which it holds exclusive rights to this product.
APEIRON’s key projects and technologies are bolstered by a strong patent portfolio with broad territorial coverage. Our development expertise is validated through partnerships with leading global pharmaceutical companies and academic institutions.
Location: Austria, Vienna
Employees: 11-50
Founded date: 2003
Investors 1
| Date | Name | Website |
| - | Medison Ve... | medisonven... |
Mentions in press and media 5
| Date | Title | Description |
| 12.10.2021 | APEIRON Biologics : commences clinical COVID-19 trial with inhaled APN01 | DGAP-News: APEIRON Biologics AG / Key word(s): Study APEIRON Biologics commences clinical COVID-19 trial with inhaled APN01 12.10.2021 / 08:00 The issuer is solely responsible for the content of this announcement. APEIRON Biologics commence... |
| 06.07.2021 | APEIRON Biologics : launches next clinical trial with innovative cancer therapy APN401 | DGAP-News: APEIRON Biologics AG / Key word(s): Study APEIRON Biologics launches next clinical trial with innovative cancer therapy APN401 06.07.2021 / 08:00 The issuer is solely responsible for the content of this announcement. APEIRON Biol... |
| 01.06.2021 | APEIRON Biologics : Announces Changes to Management and Supervisory Boards | DGAP-News: APEIRON Biologics AG / Key word(s): Personnel APEIRON Biologics Announces Changes to Management and Supervisory Boards 01.06.2021 / 10:00 The issuer is solely responsible for the content of this announcement. APEIRON Biologics An... |
| 19.05.2021 | APEIRON Biologics' : APN01 selected for large-scale US trial in COVID-19 | DGAP-News: APEIRON Biologics AG / Key word(s): Study APEIRON Biologics' APN01 selected for large-scale US trial in COVID-19 19.05.2021 / 09:00 The issuer is solely responsible for the content of this announcement. APEIRON Biologics' APN01 s... |
| 01.04.2020 | Coronavirus Business Tracker: How The Private Sector Is Fighting The Covid-19 Pandemic | Alain Mérieux, founder of BioMérieux.AFP via Getty Images |